Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 1/2014

Open Access 01-02-2014 | Research article

Increased frequency of Th17 cells in systemic sclerosis is related to disease activity and collagen overproduction

Authors: Xiaoqin Yang, Ji Yang, Xiaojing Xing, Linlin Wan, Ming Li

Published in: Arthritis Research & Therapy | Issue 1/2014

Login to get access

Abstract

Introduction

Although immune dysfunction plays a role in the pathogenesis of systemic sclerosis (SSc), involvement of T helper 17 (Th17) and T regulatory (Treg) cells remains unclear. We aimed to investigate the presence of Th17 and Treg cells in SSc patients and the role of Th17 cells in collagen production in SSc fibroblasts.

Methods

We analyzed inflammatory cell profiles in the skin of 13 SSc patients by immunohistochemistry, the percentage of Th17 and Treg cells in peripheral blood mononuclear cells (PBMCs) of 45 SSc patients and 24 healthy controls by flow cytometry, gene expression in PBMCs by real-time reverse transcription-polymerase chain reaction and interleukin-17 (IL-17) in sera and culture supernatants by enzyme-linked immunosorbent assay. We also investigated the effect of Th17 cell-derived IL-17 on fibroblast growth and collagen production.

Results

Infiltration of inflammatory cells including IL-17+ and Foxp3+ lymphocytes was detected in the skin of patients with early SSc. The percentages of circulating Th17 cells and IL-17 production were elevated in samples from patients with active SSc, whereas the percentage of circulating Treg cells was not affected. The number of Th17 cells was closely related to disease activity. IL-17 from SSc patients promoted fibroblast growth and collagen production, whereas IL-17 neutralizing antibody effectively blocked collagen production.

Conclusion

SSc progression might be linked to expansion of circulating Th17 cells and increased infiltration of IL-17+ cells in skin. Th17-derived IL-17 is involved in fibroblast growth and collagen production. IL-17 blocking antibody may be a useful tool for intervention in the fibrotic course of SSc.
Appendix
Available only for authorised users
Literature
1.
2.
Baraut J, Michel L, Verrecchia F, Farge D: Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis. Autoimmun Rev. 2010, 10: 65-73. 10.1016/j.autrev.2010.08.003.CrossRefPubMed
3.
Sakkas LI, Platsoucas CD: Is systemic sclerosis an antigen-driven T cell disease?. Arthritis Rheum. 2004, 50: 1721-1733. 10.1002/art.20315.CrossRefPubMed
4.
Giovannetti A, Rosato E, Renzi C, Maselli A, Gambardella L, Giammarioli AM: Analyses of T cell phenotype and function reveal an altered T cell homeostasis in systemic sclerosis: correlations with disease severity and phenotypes. Clin Immunol. 2010, 137: 122-133. 10.1016/j.clim.2010.06.004.CrossRefPubMed
5.
Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM: Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005, 6: 1123-1132. 10.1038/ni1254.CrossRefPubMed
6.
Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH: A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005, 6: 1133-1141. 10.1038/ni1261.CrossRefPubMedPubMedCentral
7.
Nakashima T, Jinnin M, Yamane K, Honda N, Kajihara I, Makino T: Impaired IL-17 signaling pathway contributes to the increased collagen expression in scleroderma fibroblasts. J Immunol. 2012, 188: 3573-3583. 10.4049/jimmunol.1100591.CrossRefPubMed
8.
Kurasawa K, Hirose K, Sano H, Endo H, Shinkai H, Nawata Y: Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum. 2000, 43: 2455-2463. 10.1002/1529-0131(200011)43:11<2455::AID-ANR12>3.0.CO;2-K.CrossRefPubMed
9.
Radstake TR, van Bon L, Broen J, Hussiani A, Hesselstrand R, Wuttge DM: The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes. PLoS One. 2009, 4: e5903-10.1371/journal.pone.0005903.CrossRefPubMedPubMedCentral
10.
Rodriguez-Reyna TS, Furuzawa-Carballeda J, Cabiedes J, Fajardo-Hermosillo LD, Martinez-Reyes C, Diaz-Zamudio M: Th17 peripheral cells are increased in diffuse cutaneous systemic sclerosis compared with limited illness: a cross-sectional study. Rheumatol Int. 2011, 32: 2653-2660.CrossRefPubMed
11.
Truchetet ME, Brembilla NC, Montanari E, Allanore Y, Chizzolini C: Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease. Arthritis Res Ther. 2011, 13: R166-10.1186/ar3486.CrossRefPubMedPubMedCentral
12.
Yang J, Chu Y, Yang X, Gao D, Zhu L, Yang X: Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum. 2009, 60: 1472-1483. 10.1002/art.24499.CrossRefPubMed
13.
Shevach EM: Regulatory T, cells in autoimmmunity. Annu Rev Immunol. 2000, 18: 423-449. 10.1146/annurev.immunol.18.1.423.CrossRefPubMed
14.
Sakaguchi S: Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol. 2004, 22: 531-562. 10.1146/annurev.immunol.21.120601.141122.CrossRefPubMed
15.
Mucida D, Park Y, Kim G, Turovskaya O, Scott I, Kronenberg M: Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science. 2007, 317: 256-260. 10.1126/science.1145697.CrossRefPubMed
16.
Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006, 441: 235-238. 10.1038/nature04753.CrossRefPubMed
17.
Khoury SJ: Th17 and Treg balance in systemic sclerosis. Clin Immunol. 2011, 139: 231-232. 10.1016/j.clim.2011.03.014.CrossRefPubMed
18.
Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980, 23: 581-590. 10.1002/art.1780230510.CrossRef
19.
LeRoy EC, Medsger TA: Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001, 28: 1573-1576.PubMed
20.
Valentini G, Della Rossa A, Bombardieri S, Bencivelli W, Silman AJ, D’Angelo S: European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis. 2001, 60: 592-598. 10.1136/ard.60.6.592.CrossRefPubMedPubMedCentral
21.
Mathian A, Parizot C, Dorgham K, Trad S, Arnaud L, Larsen M: Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions. Ann Rheum Dis. 2012, 71: 1227-1234. 10.1136/annrheumdis-2011-200709.CrossRefPubMed
22.
Steen VD, Medsger TA: Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000, 43: 2437-2444. 10.1002/1529-0131(200011)43:11<2437::AID-ANR10>3.0.CO;2-U.CrossRefPubMed
23.
Zhu L, Gao D, Yang J, Li M: Characterization of the phenotype of high collagen-producing fibroblast clones in systemic sclerosis, using a new modified limiting-dilution method. Clin Exp Dermatol. 2012, 37: 395-403. 10.1111/j.1365-2230.2011.04254.x.CrossRefPubMed
24.
Sollazzo D, Trabanelli S, Curti A, Vianelli N, Lemoli RM, Catani L: Circulating CD4+ CD161+ CD196+ Th17 cells are not increased in immune thrombocytopenia. Haematologica. 2011, 96: 632-634. 10.3324/haematol.2010.038638.CrossRefPubMedPubMedCentral
25.
Acosta-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M, Lanzavecchia A: Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol. 2007, 8: 639-646. 10.1038/ni1467.CrossRefPubMed
26.
Korn T, Bettelli E, Oukka M, Kuchroo VK: IL-17 and Th17 Cells. Annu Rev Immunol. 2009, 27: 485-517. 10.1146/annurev.immunol.021908.132710.CrossRefPubMed
27.
Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ: The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006, 126: 1121-1133. 10.1016/j.cell.2006.07.035.CrossRefPubMed
28.
Roumm AD, Whiteside TL, Medsger TA, Rodnan GP: Lymphocytes in the skin of patients with progressive systemic sclerosis: quantification, subtyping, and clinical correlations. Arthritis Rheum. 1984, 27: 645-653. 10.1002/art.1780270607.CrossRefPubMed
29.
Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J: Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 2007, 445: 648-651. 10.1038/nature05505.CrossRefPubMed
30.
Nistala K, Moncrieffe H, Newton KR, Varsani H, Hunter P, Wedderburn LR: Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers. Arthritis Rheum. 2008, 58: 875-887. 10.1002/art.23291.CrossRefPubMedPubMedCentral
31.
Louten J, Boniface K, de Waal MR: Development and function of TH17 cells in health and disease. J Allergy Clin Immunol. 2009, 123: 1004-1011. 10.1016/j.jaci.2009.04.003.CrossRefPubMed
32.
Yang J, Yang X, Zou H, Chu Y, Li M: Recovery of the immune balance between Th17 and regulatory T cells as a treatment for systemic lupus erythematosus. Rheumatology. 2011, 50: 1366-1372. 10.1093/rheumatology/ker116.CrossRefPubMed
33.
Slobodin G, Ahmad MS, Rosner I, Peri R, Rozenbaum M, Kessel A: Regulatory T cells (CD4(+)CD25(bright)FoxP3(+)) expansion in systemic sclerosis correlates with disease activity and severity. Cell Immunol. 2010, 261: 77-80. 10.1016/j.cellimm.2009.12.009.CrossRefPubMed
34.
Radstake TR, van Bon L, Broen J, Wenink M, Santegoets K, Deng Y: Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFbeta expression. PLoS One. 2009, 4: e5981-10.1371/journal.pone.0005981.CrossRefPubMedPubMedCentral
Metadata
Title
Increased frequency of Th17 cells in systemic sclerosis is related to disease activity and collagen overproduction
Authors
Xiaoqin Yang
Ji Yang
Xiaojing Xing
Linlin Wan
Ming Li
Publication date
01-02-2014
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2014
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar4430

Other articles of this Issue 1/2014

Arthritis Research & Therapy 1/2014 Go to the issue

Research article

Vitamin D levels in Indian systemic lupus erythematosus patients: association with disease activity index and interferon alpha

Research article

Serum nitrated nucleosome levels in patients with systemic lupus erythematosus: a retrospective longitudinal cohort study

Letter

Response to ‘Remarkable prevalence of celiac disease in patients with irritable bowel syndrome plus fibromyalgia in comparison with those with isolated irritable bowel syndrome: a case-finding study’

Research article

Intra-articular hyaluronic acid injection versus oral non-steroidal anti-inflammatory drug for the treatment of knee osteoarthritis: a multi-center, randomized, open-label, non-inferiority trial

Research article

ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial

Letter

Response to ‘Remarkable prevalence of celiac disease in patients with irritable bowel syndrome plus fibromyalgia in comparison with those with isolated irritable bowel syndrome: a case-finding study’ – authors’ reply
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits